Blueprint Medicines Corp (NAS:BPMC)
$ 96.53 -1.09 (-1.12%) Market Cap: 6.13 Bil Enterprise Value: 5.94 Bil PE Ratio: 0 PB Ratio: 19.54 GF Score: 81/100

Q4 2022 Blueprint Medicines Corp Earnings Call Transcript

Feb 16, 2023 / 01:00PM GMT
Release Date Price: $44.71 (+1.54%)
Operator

Good morning, and welcome to the Blueprint Medicines Conference Call. (Operator Instructions) Please be advised, that this call is being recorded.

At this time, I'd like to turn it over to Jenna Cohen, Head of Investor Relations at Blueprint Medicines. Please proceed.

Jenna Cohen
Blueprint Medicines Corporation - Senior Director & Head of IR

Thank you, operator. Good morning, everyone. Welcome to Blueprint Medicines Fourth Quarter and Full-Year 2022 Financial and Operating Results Conference Call. This morning, we issued a press release, which outlines the topics we plan to discuss today. You can access the press release, as well as the slides that we'll be reviewing today by going to the Investor section of our website at www.blueprintmedicines.com.

Today on our call, Kate Haviland, our Chief Executive Officer, will provide a perspective on Blueprint's 2022 accomplishments and how that positions us to continue to grow and drive value in 2023. Philina Lee, our

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot